{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:49:31Z","timestamp":1791575371486,"version":"4.3.4"},"reference-count":17,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.clinthera.2016.11.007","type":"journal-article","created":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T16:24:22Z","timestamp":1480523062000},"page":"2526-2532","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["The US Food and Drug Administration\u2019s Risk Evaluation and Mitigation Strategy (REMS) Program \u2013 Current Status and Future Direction"],"prefix":"10.1016","volume":"38","author":[{"given":"Jasmanda","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhaeri","family":"Juhaeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2016.11.007_bib1","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, US Department of Health and Human Services. Guidance for industry: format and content of proposed Risk Evaluation and Mitigation Strategies (REMS), REMS assessments, and proposed REMS modifications: draft guidance. September 2009 [online]. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceCompliance.RegulatoryInformation\/Guidances\/UCM184128.pdf. Accessed August 11, 2016."},{"key":"10.1016\/j.clinthera.2016.11.007_bib2","unstructured":"Approved Risk Evaluation and Mitigation Strategies (REMS) [online]. http:\/\/www.accessdata.fda.gov\/scripts\/cder\/rems\/index.cfm?event=RemsData.page. Accessed August 11, 2016."},{"key":"10.1016\/j.clinthera.2016.11.007_bib3","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, US Department of Health and Human Services. Guidance Medication Guides \u2014 Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS). [online]. http:\/\/www.fda.gov\/downloads\/Drugs\/...\/Guidances\/UCM244570.pdf. Accessed August 11, 2016"},{"key":"10.1016\/j.clinthera.2016.11.007_bib4","unstructured":"March 8, 2013 REMS Update for PDUFA Stakeholders. [online]. http:\/\/www.fda.gov\/downloads\/ForIndustry\/UserFees\/PrescriptionDrugUserFee\/UCM354218.pdf. Accessed November 1, 2016."},{"key":"10.1016\/j.clinthera.2016.11.007_bib5","unstructured":"July 25-26, 2013 FDA Public Meeting - Standardizing and Evaluating REMS. [online]. http:\/\/www.fda.gov\/downloads\/ForIndustry\/UserFees\/PrescriptionDrugUserFee\/UCM363676.pdf. Accessed November 1, 2016."},{"key":"10.1016\/j.clinthera.2016.11.007_bib6","unstructured":"REMS Integration Initiative [online]. http:\/\/www.fda.gov\/ForIndustry\/UserFees\/PrescriptionDrugUserFee\/ucm350852.htm. Accessed August 11, 2016."},{"key":"10.1016\/j.clinthera.2016.11.007_bib7","unstructured":"October 5-6, 2015 FDA Public Meeting - Risk Evaluation and Mitigation Strategies (REMS): Understanding and Evaluating Their Impact on the Health Care Delivery System and Patient Access. [online]. http:\/\/www.fda.gov\/Drugs\/NewsEvents\/ucm441308.htm. Accessed August 11, 2016."},{"key":"10.1016\/j.clinthera.2016.11.007_bib9","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1056\/NEJMoa0803778","article-title":"for the ATHENA Investigators. Effect of dronedarone on cardio- vascular events in atrial fibrillation","volume":"360","author":"Hohnloser","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.11.007_bib10","unstructured":"Multaq Risk Evaluation and Mitigation Strategy (REMS) [online]. http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/UCM187494.pdf. Accessed September 1, 2016"},{"key":"10.1016\/j.clinthera.2016.11.007_bib11","first-page":"1483","article-title":"Evaluation of dronedarone use in the US patient population between 2009 and 2010: a descriptive study using a claims database","volume":"33","author":"Gao","year":"2011","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2016.11.007_bib12","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.clinthera.2014.01.002","article-title":"Assessment of dronedarone utilization using US Claims Databases","volume":"36","author":"Wu","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2016.11.007_bib13","unstructured":"Public Law No. 112-144, 126 Stat. 993 (July 9, 2012) [online]. http:\/\/www.fda.gov\/RegulatoryInformation\/Legislation\/SignificantAmendmentstotheFDCAct\/FDASIA\/ucm20027187.htm. Accessed November 1, 2016."},{"key":"10.1016\/j.clinthera.2016.11.007_bib14","unstructured":"PDUFA Reauthorization Performance Goals and Procedures Fiscal Years 2013 through 2017. [online]. http:\/\/www.fda.gov\/downloads\/forindustry\/userfees\/prescriptiondruguserfee\/ucm270412.pdf. Accessed November 1, 2016."},{"key":"10.1016\/j.clinthera.2016.11.007_bib15","unstructured":"Report: Standardizing and Evaluating Risk Evaluation and Mitigation Strategies [online]. http:\/\/101.96.10.70\/www.fda.gov\/downloads\/ForIndustry\/UserFees\/PrescriptionDrugUserFee\/UCM415751.pdf. Accessed November 1, 2016."},{"key":"10.1016\/j.clinthera.2016.11.007_bib16","unstructured":"Duke Expert Workshop: REMS Patient Counseling [online]. https:\/\/healthpolicy.duke.edu\/events\/risk-evaluation-and-mitigation-strategies-improving-benefit-risk-counseling-between-providers. Accessed April 14, 2016."},{"key":"10.1016\/j.clinthera.2016.11.007_bib17","unstructured":"PDUFA\u00a0Stakeholders Meeting (REMS Integration Initiative) [online]. https:\/\/healthpolicy.duke.edu\/sites\/default\/files\/atoms\/files\/slides_6_7_16_am_ada.pdf. Accessed September 1, 2016."},{"key":"10.1016\/j.clinthera.2016.11.007_bib18","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/pds.3859","article-title":"Benefit-Risk Assessment, Communication, and Evaluation (BRACE) throughout the life cycle of therapeutic products: overall perspective and role of the pharmacoepidemiologist","volume":"24","author":"Radawski","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816308451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816308451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T15:47:32Z","timestamp":1542296852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291816308451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":17,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0149291816308451"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.11.007","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The US Food and Drug Administration\u2019s Risk Evaluation and Mitigation Strategy (REMS) Program \u2013 Current Status and Future Direction","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}